Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138880225> ?p ?o ?g. }
- W2138880225 abstract "Enhancer of zeste homolog 2 (EZH2), a member of the polycomb group proteins, has been shown to promote cancer progression and breast cancer stem cell (CSC) expansion. Breast CSCs are associated with resistance to radiation in inflammatory breast cancer (IBC), a rare but aggressive variant of breast cancer. In this retrospective study, we examined the clinical role of EZH2 in locoregional recurrence (LRR) of IBC patients treated with radiation. 62 IBC patients who received radiation (7 pre-operative, 55 post-operative) and had adequate follow up to assess LRR were the subject of this study. Positive EZH2 status was defined as nuclear immunohistochemical staining in at least 10% of invasive cancer cells. Association of EZH2 expression with clinicopathologic features were evaluated using the Chi-square statistic and actuarial LRR free survival (LRFS) was determined using the Kaplan-Meier method. The median follow-up for this cohort was 33.7 months, and the 5-year overall LRFS rate was 69%. Of the 62 patients, 16 (25.8%) had LRR, and 15 out of 16 LRR occurred in EZH2 expressing cases. Univariate analysis indicated that patients who had EZH2-positive IBC had a significantly lower 5-year locoregional free survival (LRFS) rate than patients who had EZH2-negative IBC (93.3% vs. 59.1%; P = 0.01). Positive EZH2 expression was associated significantly with negative ER status (97.1% in ER- vs 48.1% in ER+; P < 0.0001) and triple-negative receptor status (P = 0.0001) and all triple-negative tumors were EZH2-positive. In multivariate analysis, only triple negative status remained an independent predictor of worse LRFS (hazard ratio 5.64, 95% CI 2.19 – 14.49, P < 0.0001). EZH2 correlates with locoregional recurrence in IBC patients who received radiation treatment. EZH2 expression status may be used in addition to receptor status to identify a subset of patients with IBC who recur locally in spite of radiation and may benefit from enrollment in clinical trials testing radiosensitizers." @default.
- W2138880225 created "2016-06-24" @default.
- W2138880225 creator A5003107322 @default.
- W2138880225 creator A5016731809 @default.
- W2138880225 creator A5045166646 @default.
- W2138880225 creator A5060592779 @default.
- W2138880225 creator A5073488441 @default.
- W2138880225 creator A5076834432 @default.
- W2138880225 creator A5080832682 @default.
- W2138880225 creator A5081939632 @default.
- W2138880225 creator A5088293773 @default.
- W2138880225 creator A5088814426 @default.
- W2138880225 date "2014-07-23" @default.
- W2138880225 modified "2023-10-12" @default.
- W2138880225 title "EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer" @default.
- W2138880225 cites W1545202350 @default.
- W2138880225 cites W1977836335 @default.
- W2138880225 cites W1990136194 @default.
- W2138880225 cites W1996318057 @default.
- W2138880225 cites W1996898892 @default.
- W2138880225 cites W2008843346 @default.
- W2138880225 cites W2030246401 @default.
- W2138880225 cites W2033323162 @default.
- W2138880225 cites W2043664943 @default.
- W2138880225 cites W2054275987 @default.
- W2138880225 cites W2060551076 @default.
- W2138880225 cites W2085178889 @default.
- W2138880225 cites W2090539023 @default.
- W2138880225 cites W2118758371 @default.
- W2138880225 cites W2125519401 @default.
- W2138880225 cites W2138306504 @default.
- W2138880225 cites W2143302156 @default.
- W2138880225 cites W2157981846 @default.
- W2138880225 cites W2159078391 @default.
- W2138880225 cites W2159640574 @default.
- W2138880225 cites W2163292580 @default.
- W2138880225 cites W2165708610 @default.
- W2138880225 doi "https://doi.org/10.1186/s13046-014-0058-9" @default.
- W2138880225 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4431485" @default.
- W2138880225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25051981" @default.
- W2138880225 hasPublicationYear "2014" @default.
- W2138880225 type Work @default.
- W2138880225 sameAs 2138880225 @default.
- W2138880225 citedByCount "21" @default.
- W2138880225 countsByYear W21388802252015 @default.
- W2138880225 countsByYear W21388802252016 @default.
- W2138880225 countsByYear W21388802252017 @default.
- W2138880225 countsByYear W21388802252018 @default.
- W2138880225 countsByYear W21388802252019 @default.
- W2138880225 countsByYear W21388802252020 @default.
- W2138880225 countsByYear W21388802252021 @default.
- W2138880225 crossrefType "journal-article" @default.
- W2138880225 hasAuthorship W2138880225A5003107322 @default.
- W2138880225 hasAuthorship W2138880225A5016731809 @default.
- W2138880225 hasAuthorship W2138880225A5045166646 @default.
- W2138880225 hasAuthorship W2138880225A5060592779 @default.
- W2138880225 hasAuthorship W2138880225A5073488441 @default.
- W2138880225 hasAuthorship W2138880225A5076834432 @default.
- W2138880225 hasAuthorship W2138880225A5080832682 @default.
- W2138880225 hasAuthorship W2138880225A5081939632 @default.
- W2138880225 hasAuthorship W2138880225A5088293773 @default.
- W2138880225 hasAuthorship W2138880225A5088814426 @default.
- W2138880225 hasBestOaLocation W21388802251 @default.
- W2138880225 hasConcept C104317684 @default.
- W2138880225 hasConcept C121608353 @default.
- W2138880225 hasConcept C126322002 @default.
- W2138880225 hasConcept C143998085 @default.
- W2138880225 hasConcept C144301174 @default.
- W2138880225 hasConcept C150194340 @default.
- W2138880225 hasConcept C204232928 @default.
- W2138880225 hasConcept C2778740770 @default.
- W2138880225 hasConcept C2779013556 @default.
- W2138880225 hasConcept C2780110267 @default.
- W2138880225 hasConcept C38180746 @default.
- W2138880225 hasConcept C50171091 @default.
- W2138880225 hasConcept C509974204 @default.
- W2138880225 hasConcept C530470458 @default.
- W2138880225 hasConcept C55493867 @default.
- W2138880225 hasConcept C71924100 @default.
- W2138880225 hasConcept C86803240 @default.
- W2138880225 hasConceptScore W2138880225C104317684 @default.
- W2138880225 hasConceptScore W2138880225C121608353 @default.
- W2138880225 hasConceptScore W2138880225C126322002 @default.
- W2138880225 hasConceptScore W2138880225C143998085 @default.
- W2138880225 hasConceptScore W2138880225C144301174 @default.
- W2138880225 hasConceptScore W2138880225C150194340 @default.
- W2138880225 hasConceptScore W2138880225C204232928 @default.
- W2138880225 hasConceptScore W2138880225C2778740770 @default.
- W2138880225 hasConceptScore W2138880225C2779013556 @default.
- W2138880225 hasConceptScore W2138880225C2780110267 @default.
- W2138880225 hasConceptScore W2138880225C38180746 @default.
- W2138880225 hasConceptScore W2138880225C50171091 @default.
- W2138880225 hasConceptScore W2138880225C509974204 @default.
- W2138880225 hasConceptScore W2138880225C530470458 @default.
- W2138880225 hasConceptScore W2138880225C55493867 @default.
- W2138880225 hasConceptScore W2138880225C71924100 @default.
- W2138880225 hasConceptScore W2138880225C86803240 @default.
- W2138880225 hasIssue "1" @default.
- W2138880225 hasLocation W21388802251 @default.
- W2138880225 hasLocation W21388802252 @default.